GSK reportedly being investigated for Mideast behavior

Share this article:

The Wall Street Journal reported Sunday that GlaxoSmithKline is allegedly being investigated over unethical behavior in the Middle East. The WSJ says it has seen emails with allegations that track closely with previous allegations of improper behavior in China that plagued the company over the last year.

An inside source tells the paper that he believes GSK “practices in Iraq violate the FCPA and the UK Bribery Act.” FCPA refers to the US Foreign Corrupt Practices Act. Allegations include paying government-supported healthcare providers to double as sales representatives and providing “high fees...in exchange for promoting and prescribing its drugs.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.